BioCentury
ARTICLE | Financial News

AbbVie Ventures, HealthCap lead Carisma's $53M series A

June 29, 2018 2:52 PM UTC

Macrophage immunotherapy company Carisma Therapeutics Inc. (Philadelphia, Pa.) raised $53 million in a series A round led by existing investors AbbVie Ventures and HealthCap. Existing investors IP Group plc (LSE:IPO), Penn Medicine and Grazia Equity, and new investors Wellington Partners, TPG Biotech, MRL Ventures Fund and Agent Capital participated.

Carisma CEO Steven Kelly told BioCentury the round should give the company (formerly Carma Therapeutics Inc.) three years of runway. While the company is not disclosing how much it drew down, Kelly did say it was a “pretty sizable amount.”...

BCIQ Company Profiles

Carisma Therapeutics Inc.